

**USSN 08/700,565  
GRUENBERG  
AMENDMENT**

Claims 22-25, 28, 29, 31-33, 155-158, 164-168 and 170-172, 211, 212, 213, 216 and 217 are pending.

A clean copy of claim 211, as requested, is provided herewith. Claim 211 was amended in the Amendment filed, 08/15/01, in Response to the Office Action mailed on February 13, 2001, with only the marked-up version of the claim enclosed.

A marked up copy of claim 211 showing the amendment originally filed on 8/15/01 is appended hereto.

\* \* \*


In view of the above remarks and the amendments and remarks of record, consideration and allowance of the application are respectfully requested.

Respectfully submitted,  
HELLER EHRMAN WHITE & MCAULIFFE LLP

By:

  
Stephanie Seidman  
Registration No. 33,779

Attorney Docket No. 24731-500B  
**Address all correspondence to:**  
HELLER EHRMAN WHITE & MCAULIFFE LLP  
4350 La Jolla Village Drive  
San Diego, CA 92122-9164  
Telephone: 858 450-8400  
Facsimile: 858 587-5360



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MICHEAL L. GRUENBERG

Serial No.: 08/700,565

Filed: July 25, 1996

For: AUTOLOGOUS IMMUNE CELL  
THERAPY: CELL COMPOSITIONS,  
METHODS AND APPLICATIONS TO  
TREATMENT OF HUMAN DISEASE

Art Unit: 1644

Examiner: Schwadron, R

I hereby certify that this paper and the attached  
papers are being deposited with the United  
States Postal Service as First Class mail in an  
envelope addressed to:  
Commissioner for Patents  
Washington, D.C. 20231, on this date.

11/14/01  
Date

Kelly Fischer

RECEIVED  
FEB 04 2002  
TECHNICAL CENTER 1600/2900

MARKED UP CLAIMS (37 C.F.R. § 1.121)

Please amend claim 211 as follows:

211. (Twice Amended) A method for generating immune cells for  
autologous cellular immunotherapy, comprising:

collecting leukocyte containing material from a mammal;

differentiating the leukocytes into Th1 [or Th2] cells; and

exposing the leukocyte containing material to two or more mitogenic  
monoclonal antibodies to induce *in vitro* cell proliferation sufficient for infusion into  
the mammal for use in an immunotherapy treatment, wherein the *in vitro* cell  
proliferation is produced without the use of exogenous interleukin-2.